logo-loader
viewGenprex, Inc.

Genprex boss Rodney Varner gives second live interview on nationally syndicated TV and radio show the ‘Big Biz Show’

During the interview, among other topics, Varner discussed Genprex’s lead drug candidate, GPX-001, for non-small cell lung cancer and how the company is forging ahead during the coronavirus (COVID-19) pandemic

Genprex, Inc. -
The emmy award-winning show was named by TALKERS Magazine as one of the “Top 10 Most Influential Financial Shows”

Genprex Inc. (NASDAQ:GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, has said its chairman and chief executive officer, Rodney Varner, has participated in a second-round live interview on the ‘Big Biz Show’, an emmy award-winning nationally syndicated TV and radio show.

During the interview Varner discussed Genprex’s lead drug candidate, GPX-001, for non-small cell lung cancer; how the company is forging ahead during the coronavirus (COVID-19) pandemic; company catalysts coming in the next 18 months; and the recent National Institutes of Health $2.59 million research grant awarded to its collaborators at the University of Pittsburgh for its licensed diabetes gene therapy.

READ: Genprex advisor George Gittes wins $2.6 million NIH grant to develop diabetes gene therapy, GPX-002

The ‘Big Biz Show’ covers current business events, internet-related issues and other hot topics in the business world and is seen and heard in over 100 million broadcast TV homes, 150 radio stations in the US and in 175 countries. The emmy award-winning show was named by TALKERS Magazine as one of the “Top 10 Most Influential Financial Shows.”

A replay of the interview is available for viewing on the company’s website at https://bit.ly/2Esvq05.

Varner’s first live appearance on the Big Biz Show in June 2020, visit Genprex’s website: https://www.genprex.com/videos/

Contact the author at [email protected]

Quick facts: Genprex, Inc.

Price: 3.8 USD

NASDAQ:GNPX
Market: NASDAQ
Market Cap: $147.71 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Genprex, Inc. named herein, including the promotion by the Company of Genprex, Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Genprex Inc making progress on branding for its lead cancer therapy, Oncoprex

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner tells Proactive the biotech has initiated the first phase of branding for its lead drug candidate, Oncoprex, an immunogene therapy to treat non-small cell lung cancer. Varner says the Texas-based company has completed the creation and submission of...

on 6/8/19

2 min read